ERIC 2018 Session III
CLL Treatment: State-of-the-art
Session III of ERIC 2018 meeting featured experts Jacqueline Barrientos, MD, and William Wierda, MD, PhD, presenting on the potential pathways for inhibition and whether combining treatment modalities are actually useful or not.
Presentations
Pathway Inhibitors for CLL Therapy
Jacqueline Barrientos, MD
Feinstein Institute for Medical Research, Manhasset, NY
Feinstein Institute for Medical Research, Manhasset, NY
26 October, 2018
Jacqueline Barrientos, MD, from Feinstein Institute for Medical Research, Manhasset, NY, discusses pathway inhibitors for CLL therapy.
Combining Treatment Modalities: Useful or Superfluous?
William Wierda, MD, PhD
MD Anderson Cancer Center, Houston, TX
MD Anderson Cancer Center, Houston, TX
26 October, 2018
William Wierda, MD, PhD, from MD Anderson Cancer Center, Houston, TX, talks about combining treatment modalities.
